The Bicyclo Ring System Consists Of The Five-membered Hetero Ring And A Benzene Ring (e.g., Indole, Etc.) Patents (Class 514/415)
  • Patent number: 12005077
    Abstract: The present invention introduces an ophthalmic solution containing halo-fullerenes. When the spherical fullerene carbon cages are functionalized with halogens, the resulting halo-fullerenes demonstrate sustained antimicrobial activity. Fullerenes are also characterized by unique electron properties that impart antioxidant capabilities as free radical scavengers. Nonetheless, far smaller than ocular tissue cells, halo-fullerenes are biocompatible—and capable of penetrating intricate barriers, like the cornea and conjunctiva, with potential to achieve greater efficacy and symptom relief in chronic dry eye than conventional treatments. With remarkable surface area, halo-fullerenes also allow customization and possess a unique molecular architecture for broader applications. This multifunctional solution thus imparts antimicrobial activity, antioxidative protection, molecular lubrication, and shielding from external irritants while penetrating dense ocular structures.
    Type: Grant
    Filed: September 28, 2023
    Date of Patent: June 11, 2024
    Inventors: Terry Earl Brady, Anthony Lee Dellinger, Lowell Hughes, Melinda K. M. Goddard, Christopher E. Starr, Abed Alqader Ibrahim
  • Patent number: 11896600
    Abstract: The invention provides a composition comprising one or more hydroxytryptamides and method of its use in the treatment of neurodegenerative disorders. The invention includes embodiments wherein the composition comprises caffeine and chlorogenic acids. The composition finds use in the treatment of Alzheimer's disease and Parkinson's disease, including providing neuroprotection against the advancement of the symptoms of these disorders.
    Type: Grant
    Filed: September 20, 2020
    Date of Patent: February 13, 2024
    Assignee: Vidya Herbs, Inc.
    Inventor: Kodimule Shyam Prasad
  • Patent number: 11845727
    Abstract: Disclosed are novel aldehyde and ketone psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with an aldehyde or ketone group containing compound.
    Type: Grant
    Filed: September 23, 2022
    Date of Patent: December 19, 2023
    Assignee: ENVERIC BIOSCIENCES CANADA INC.
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • Patent number: 11744837
    Abstract: This invention provides new methods for a) identifying Cushing's Syndrome patients at high risk of developing hypokalemia during glucocorticoid receptor modulator (GRM) treatment, and b) for prophylactically treating such patients to prevent, or reduce the severity of, hypokalemia. Patients at such high risk may be identified prior to their developing hypokalemia. Such a patient may be an adult patient with endogenous Cushing's Syndrome having type 2 diabetes mellitus or glucose intolerance to control hyperglycemia secondary to hypercortisolism. Patients may be identified by an above-threshold level of ACTH or cortisol in a patient sample taken post-GRM administration or pre-GRM administration, respectively. Upon identifying such a patient prior to the development of low potassium, the present methods provide for prophylactically treating the patient by administration of one or more hypokalemia treatments concurrently with an increased dose of GRM or with an initial dose of GRM to prevent hypokalemia.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: September 5, 2023
    Assignee: Corcept Therapeutics, Inc.
    Inventor: Andreas Moraitis
  • Patent number: 11739060
    Abstract: The disclosure relates to 5-methoxy-N,N-diallyltryptamine (“5-MeO-DALT”), bis-(5-meth-oxy-N,N-di-allyl-tryptammonium) fumarate (“5-MeO-DALT fumarate”), and crystalline bis-(5-meth-oxy-N,N-di-allyl-tryptammonium) fumarate (“5-MeO-DALT fumarate”), compositions containing them, and the methods of treatment using them.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: August 29, 2023
    Assignee: CAAMTECH, INC.
    Inventor: Andrew R. Chadeayne
  • Patent number: 11723894
    Abstract: The present application provides a combination product for the treatment and/or prevention of psychiatric and/or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and/or psychedelic side effects, and (ii) a 5-HT2A receptor antagonist which alleviates and/or removes the hallucinogenic and/or psychedelic side effects caused by the first compound.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: August 15, 2023
    Assignee: TERRAN BIOSCIENCES, INC.
    Inventors: Ana Maria Perez Castillo, Jordi Riba Serrano, Jose Ángel Morales García
  • Patent number: 11653876
    Abstract: A CAP detection device configured to acquire pulse wave data of a subject, derive a baseline of the data and an envelope of the baseline, identify a local maximum point of the envelope and determine, as CAP candidate points, a first local maximum point of the baseline before the local maximum point of the envelope and a second local maximum point of the baseline after the local maximum point, and identify, for each CAP candidate point, a third local maximum point of the baseline before the CAP candidate point and a local minimum point of the baseline between the CAP candidate point and the third local maximum point and detect the CAP candidate point as a CAP based on an evaluation value obtained from a difference between the CAP candidate point and the third local maximum point and a difference between the CAP candidate point and the local minimum point.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: May 23, 2023
    Assignee: CASIO COMPUTER CO., LTD.
    Inventors: Mitsuyasu Nakajima, Kouichi Nakagome, Takashi Yamaya, Yasushi Maeno
  • Patent number: 11607406
    Abstract: Compositions and methods are described for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation. The method comprises administering an effective amount of tetrahydropalmatine or its derivative or Rhizoma Corydalis extract containing composition to a human male on an as-needed basis shortly before sexual activity to delay ejaculation.
    Type: Grant
    Filed: March 1, 2020
    Date of Patent: March 21, 2023
    Inventor: Tianxin Wang
  • Patent number: 11602521
    Abstract: A composition including N,N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof capable of exhibiting a therapeutically effective blood level of DMT from between about 20 and about 60 minutes when administered to a human. A method of treating a neurological disease or condition comprising administering buccally, sublingually, subcutaneously or intranasally to a subject in need thereof an effective amount of DMT or a pharmaceutically acceptable salt thereof, capable of exhibiting a therapeutically effective level of DMT from for between about 20 to about 60 minutes when administered to a human.
    Type: Grant
    Filed: April 26, 2022
    Date of Patent: March 14, 2023
    Assignee: ATAI LIFE SCIENCES AG
    Inventors: Srinivas G. Rao, Glenn Short
  • Patent number: 11427585
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: August 30, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Patent number: 11382876
    Abstract: The use of S-enantiomerically enriched compositions of beta blockers for treating muscle weakness. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: July 12, 2022
    Assignee: Actimed Therapeutics LTD
    Inventors: Stefan Anker, Andrew J. S. Coats
  • Patent number: 11364225
    Abstract: A treatment for symptoms of migraine and cluster headaches includes operations of providing a solution of a serotonin receptor agonist (SRA) in an active mesh nebulizer, triggering the formation of a plume of particles from the active mesh nebulizer, and delivery of the plume of particles into the lungs of a patient during an inhalation process.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: June 21, 2022
    Assignee: BN INTELLECTUAL PROPERTIES, INC.
    Inventors: Donald M. Pell, Paula Pell, Michael Spuza, Govindan Nair
  • Patent number: 11345662
    Abstract: Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: May 31, 2022
    Assignee: UCB Pharma GmbH
    Inventors: Christa E. Mueller, Cécile Pegurier, Michael Louis Robert Deligny, Ali El-Tayeb, Joerg Hockemeyer, Marie Ledecq, Joël Mercier, Laurent Provins, Nader M. Boshta, Sanjay Bhattarai, Vigneshwaran Namasivayam, Mario Funke, Lukas Schwach, Sabrina Gollos, Daniel Von Laufenberg, Anaïs Barré
  • Patent number: 11339189
    Abstract: Disclosed herein are compounds that are selective DNA primase and/or gyrase inhibitors. Further disclosed are pharmaceutical compositions comprising these compounds, and the uses of these compounds for treating disorders associated with microbial infections.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: May 24, 2022
    Assignee: B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY
    Inventor: Barak Akabayov
  • Patent number: 11242317
    Abstract: Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: February 8, 2022
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Troy E. Messick, Garry R. Smith, Allen B. Reitz, Paul M. Lieberman, Mark E. McDonnell, Yan Zhang, Venkata Velvadapu
  • Patent number: 11220491
    Abstract: The present invention relates to compounds, compositions, and methods for modulating skin pigmentation and treating or preventing UV-induced skin damage, erythema, aging of the skin, sunburn, and hyperpigmentation in a subject. The compounds, compositions, and methods of the present invention generally involve Malassezia-derived compounds, including malassezin and indirubin, and/or chemical analogs thereof. Other applications of the compounds and compositions disclosed herein include, but are not limited to, improving hyperpigmentation caused by a hyperpigmentation disorder, inducing melanocyte apoptosis, and modulating arylhydrocarbon receptor (AhR) activity, melanogenesis, melanin production, melanosome biogenesis, melanosome transfer, melanocyte activity, and melanin concentration.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: January 11, 2022
    Assignee: Versicolor Technologies, LLC
    Inventors: Michael Einziger, Ann Marie Simpson
  • Patent number: 11065266
    Abstract: The invention pertains to a method of treating melanoma by administering to a subject in need thereof, a composition comprising a therapeutically effective amount of an inhibitor of PKC-? and/or PKC-?. Non-limiting examples of an inhibitor of PKC-? and/or PKC-? include ICA-1 and ACPD. The invention also provides PKC-? and/or PKC-? as biomarkers for identifying a melanoma in a subject as likely to be responsive or non-responsive to a therapy using an inhibitor of PKC-? and/or PKC-?. Accordingly, a method of identifying a subject having a melanoma as being responsive or non-responsive to a melanoma therapy with an inhibitor of PKC-? and/or PKC-? based on the levels and/or activity of PKC-? and/or PKC-? mRNA or protein in the melanoma cells from the subject are also provided.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: July 20, 2021
    Assignees: UNIVERSITY OF SOUTH FLORIDA, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Mildred Enid Acevedo-Duncan, Wishrawana Sarathi Ratnayake, David A. Ostrov
  • Patent number: 10703716
    Abstract: Disclosed herein are antibacterial compounds, pharmaceutical compositions including the antibacterial compounds, and methods of treating bacterial infections using the compounds and compositions.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: July 7, 2020
    Assignee: Wayne State University
    Inventors: Fazlul H. Sarkar, Subhash Padhye, Bernhard Max Biersack, Hossein Salimnia
  • Patent number: 10590079
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: wherein R1, R2, R3, R4, R5, and R6 are as defined herein.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: March 17, 2020
    Assignee: Novartis AG
    Inventors: Lei Du-Cuny, Feng He, Qitao Xiao, Guoliang Xun, Qiangang Zheng
  • Patent number: 10550080
    Abstract: The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: February 4, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Ling Chen
  • Patent number: 10537554
    Abstract: The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: January 21, 2020
    Assignee: UPSHER-SMITH LABORATORIES, LLC
    Inventors: Prabhu Prabhakara, Rajesh Ramesh Patil, Piyush Gupta, Rajeev Singh Raghuvanshi, Anil N. Namboodiripad
  • Patent number: 10507199
    Abstract: Methods that include determining levels of melatonin pathway agents (melatonin, L-tryptophan, 5-hydroxytryptophan (5-HTP), serotonin, N-acetylserotonin (NAS), and melatonin receptor 1A (MT1)) in Hypoxic-ischemic brain injury in both newborns (HIE) and adults (stroke), and in ALS, and optionally administering these agents to treat these conditions.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: December 17, 2019
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Xin Wang
  • Patent number: 10501414
    Abstract: This invention relates to novel pharmaceutically-useful compounds, to methods for their preparation, and to pharmaceutical compositions and therapeutic methods for treating certain conditions.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: December 10, 2019
    Assignees: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY, FLORIDA INSTITUTE OF TECHNOLOGY
    Inventors: William S. Powell, Joshua Rokach
  • Patent number: 10421718
    Abstract: Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: September 24, 2019
    Assignee: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
    Inventors: Troy E. Messick, Garry R. Smith, Allen B. Reitz, Paul M. Lieberman, Mark E. McDonnell, Yan Zhang, Venkata Velvadapu
  • Patent number: 10377710
    Abstract: The present invention relates to a novel, improved, commercially viable and industrially advantageous process for the preparation of Silodosin of Formula (I), its pharmaceutically acceptable salts or solvates thereof. The invention relates to the preparation of considerably pure Silodosin with high yield.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: August 13, 2019
    Assignee: MANKIND PHARMA LTD.
    Inventors: Kuldeep Singh Gangwar, Anil Kumar, Bhuwan Bhashkar
  • Patent number: 10369310
    Abstract: Disclosed is an apparatus for treating a respiratory disorder. The apparatus comprises a pressure device, and a controller, including at least one processor, configured to control the pressure device to: supply, upon initiation of treatment, a flow of pressurized air to the airway of a patient at a treatment pressure according to a pre-sleep profile of pressure versus time, increase, upon detection of sleep onset of the patient, the treatment pressure to a predetermined therapeutic pressure according to a bridging profile of pressure versus time, and supply the flow of pressurized air to the airway of the patient at a therapeutic pressure.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: August 6, 2019
    Assignee: ResMed Pty Ltd
    Inventors: Dinesh Ramanan, Jeffrey Peter Armitstead, Joon-Pil Hwang, Jane Zona Mchenry, Nathan John Row
  • Patent number: 10273246
    Abstract: In one aspect, the invention relates to substituted 5H-[1,2,5]oxadiazolo [3?,4?:5,6]pyrazino[2,3-b]indole analogs, derivatives thereof, and related compound; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and A methods of treating disorders, e.g., various tumors and cancers, associated with a ?-catenin/T-cell factor interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: April 30, 2019
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Haitao Ji, Yongqiang Zhang, Min Zhang, Jonathan L. Catrow
  • Patent number: 10220024
    Abstract: An object of the present invention is to provide a cancer cell inhibitory drug, particularly a cancer stem-cell inhibitory drug, or a cancer stem-cell detection probe. A cancer cell inhibitory drug containing at least a compound represented by general formula (1).
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: March 5, 2019
    Assignee: CANON KABUSHIKI KAISHA
    Inventors: Taichi Shintou, Tsuyoshi Nomoto, Kohei Watanabe, Takeshi Miyazaki, Toshio Tanaka, Yasuhito Shimada, Yuhei Nishimura
  • Patent number: 10206902
    Abstract: The present invention concerns mono- or di-substituted indole compounds of formula (I) which are useful to prevent or treat dengue viral infections and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: February 19, 2019
    Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit Leuven
    Inventors: Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
  • Patent number: 10194918
    Abstract: The invention provides methods for reducing traumatic injury through the use of ischemic conditioning.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: February 5, 2019
    Assignee: The Hospital for Sick Children
    Inventor: Christopher Caldarone
  • Patent number: 10039703
    Abstract: The invention relates to a composition comprising 0.01% to 15% resveratrol and 0.01% to 15% of melatonin. In a preferred embodiment, the composition comprises 5% resveratrol and 0.1% melatonin. The invention also relates to the use of the said composition to reduce hair loss and/or increase regrowth of hair in a human subject.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: August 7, 2018
    Assignee: Triple Hair Inc.
    Inventor: Houfar Sekhavat
  • Patent number: 10034858
    Abstract: The present invention relates to a pharmaceutical composition for topical administration comprising a compound of formula I, 3-{4-[2-{5-chloro-1-(diphenylmethyl)-2-[2-({[2-(trifluoromethyl)benzyl]sulfonyl}amino)ethyl]-1H-indol-3-yl}ethyl]sulfonyl}phenyl}propanoic acid: or pharmaceutically acceptable salts thereof; and to methods of treating inflammation comprising topical administration of a compositions comprising a compound of formula I.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: July 31, 2018
    Assignee: Ziarco Pharma Ltd.
    Inventors: Wai Leung Liu, Lynn Purkins, Michael Yeadon
  • Patent number: 10034857
    Abstract: The invention provides stable, spray-dried, particle formulations containing a triptan, preferably sumatriptan, or a pharmaceutically acceptable salt thereof, which are useful for pulmonary administration to the respiratory tract of a patient for the treatment of disease.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: July 31, 2018
    Assignee: Civitas Therapeutics, Inc.
    Inventor: Michael M. Lipp
  • Patent number: 9951019
    Abstract: The invention provides compounds of formula (I): wherein, A, C, D, X, and Y have any of the values defined in the specification, and salts thereof. The compounds are SIRT2 inhibitors and are useful for treating SIRT2 associated conditions.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: April 24, 2018
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Liqiang Chen, Teng Ai, Swati More
  • Patent number: 9920093
    Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: March 20, 2018
    Assignee: TetraLogic Birinapant UK Ltd.
    Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin
  • Patent number: 9907841
    Abstract: Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such as botulinum neurotoxin, to the patient, are provided.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: March 6, 2018
    Assignee: Allergan, Inc.
    Inventors: Ivan Aguilar, Gustavo M. Gaxiola, Gilberto P. Paz
  • Patent number: 9902694
    Abstract: This invention relates to crystalline forms of (R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile, a modulator of the androgen receptor, and methods for the use in treatment.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: February 27, 2018
    Assignee: GlaxoSmithKline Intellectual Property (No 2) Limited
    Inventors: Istvan Kaldor, Dalin Tang
  • Patent number: 9889126
    Abstract: Described herein is a method of using a topical, pharmaceutical composition, particularly a dermatological composition, comprising naratriptan to treat rosacea and in particular erythematotelangiectatic rosacea.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: February 13, 2018
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Michel Rivier, Isabelle Carlavan, Jerome Aubert
  • Patent number: 9850262
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: December 26, 2017
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein
  • Patent number: 9840464
    Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: December 12, 2017
    Assignee: TetraLogic Birinapant UK Ltd.
    Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin
  • Patent number: 9834514
    Abstract: The present disclosure describes a method to treat conditions, including bacterial infections and cancer, using a photosensitive compound that, upon exposure to white light, can be activated. The photosensitive compound can also interact synergistically with antibiotics used concomitantly to kill drug-resistant bacteria. The photosensitive compounds can also be used to inhibit the proliferation of cancer cells.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: December 5, 2017
    Assignee: NEW MEXICO TECH RESEARCH FOUNDATION
    Inventors: Snezna Rogelj, Liliya Frolova, Alexander Kornienko, Leslie D. Edwards, Cody Champion, Kailee Zingler, Danielle Nicole Turner
  • Patent number: 9763916
    Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: September 19, 2017
    Assignee: ARCA Biopharma, Inc.
    Inventors: Michael R. Bristow, Jonathan D. Port
  • Patent number: 9758481
    Abstract: Peptides and compounds are provided that function as EWS-FLI1 protein inhibitors. The peptides and compounds have utility in the treatment of Ewing's sarcoma family of tumors. Also provided are methods of preparing the compounds and assays for identifying inhibitors of EWS-FLI1 protein.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: September 12, 2017
    Assignee: GEORGETOWN UNIVERSITY
    Inventors: Jeffrey A. Toretsky, Aykut Uren, Milton Lang Brown, Yali Kong
  • Patent number: 9725452
    Abstract: The present invention relates to heterocyclic compounds (e.g., compounds described by Formula (I)) and pharmaceutically acceptable salts thereof. The invention also features pharmaceutical compositions that include these compounds and their use in therapy for treating conditions in which necroptosis is likely to play a substantial role. The heterocyclic compounds described herein can also achieve improved activity and selectivity towards RIP1 and/or RIP3.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 8, 2017
    Assignees: Presidents and Fellows of Harvard College, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Tufts University, University of Houston
    Inventors: Junying Yuan, Alexei Degterev, Gregory D. Cuny
  • Patent number: 9693995
    Abstract: The present invention relates to a pharmaceutical composition for topical administration comprising a compound of formula I, 3-{4-[2-{5-chloro-1-(diphenylmethyl)-2-[2-({[2-(trifluoromethyl)benzyl]sulfonyl}amino)ethyl]-1H-indol-3-yl}ethyl]sulfonyl}phenyl}propanoic acid: or pharmaceutically acceptable salts thereof; and to methods of treating inflammation comprising topical administration of a compositions comprising a compound of formula I.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: July 4, 2017
    Assignee: Ziarco Pharma Limited
    Inventors: Wai Leung Liu, Lynn Purkins, Michael Yeadon
  • Patent number: 9669006
    Abstract: A dietary supplement composition is formulated in a therapeutic amount to treat and alleviate symptoms of hot flashes in a female subject, such as experiencing symptoms of perimenopause. The composition includes a phytoestrogen and lycopene in an oral dosage form. The phytoestrogen may include a plant lignan including at least one of Matairesinol, 7-hydroxymatairesinol, Secoisolariciresinol, Lariciresinol and Pinoresinol. The lycopene may include a lycopene complex having at least one of phytoene, phytofluene, beta-carotene, tocopherols and phytosterols.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: June 6, 2017
    Assignee: U.S. NUTRACEUTICALS, LLC
    Inventors: John A. Minatelli, W. Stephen Hill, Rudi E. Moerck, Jessica Engle
  • Patent number: 9670149
    Abstract: A process for preparing guanidino-functional, free radically polymerizable compounds comprises (a) combining (1) an amine compound comprising (i) at least one primary aliphatic amino group and (ii) at least one secondary aliphatic amino group, primary aromatic amino group, or secondary aromatic amino group, and (2) a guanylating agent; (b) allowing or inducing reaction of the amine compound and the guanylating agent to form a guanylated amine compound; (c) combining (1) the guanylated amine compound, and (2) a reactive monomer comprising (i) at least one ethylenically unsaturated group and (ii) at least one group that is reactive with an amino group; and (d) allowing or inducing reaction of the guanylated amine compound and the reactive monomer to form a guanidino-functional, free radically polymerizable compound.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: June 6, 2017
    Assignee: 3M Innovative Properties Company
    Inventors: Jerald K. Rasmussen, George W. Griesgraber, James I. Hembre
  • Patent number: 9649294
    Abstract: Glucagon receptor antagonist compounds are disclosed which are of long duration of action. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: May 16, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Libo Xu, Emma R. Parmee, Xibin Liao
  • Patent number: 9603836
    Abstract: The present invention relates to compound of Formula I or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula I as IDO1 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer and endometriosis. The invention also relates to a process for manufacturing compounds of Formula I.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: March 28, 2017
    Assignee: ITEOS THERAPEUTICS
    Inventors: Stefano Crosignani, Sandra Cauwenberghs, Gregory Driessens, Frederik Deroose
  • Patent number: 9554883
    Abstract: The present artificial insemination instrument may include a single use, hollow, elongate, metal pipette and a single disposable syringe that is not toxic to bovine sperm. The apparatus is used with any type of diluent that is not toxic to bovine sperm. In various embodiments, a technician may use non-sorted reduced sperm count semen straws from a bull stud, cut an unsorted semen straw into several pieces to use one piece at a time per cow, thaw one straw and mix the non-sorted semen with diluent, or use reduced sperm count semen straws filled with sex sorted semen by the manufacturer. A procedure is disclosed to use the artificial insemination instrument, reduced sperm count semen from any of the aforementioned sources, a non-toxic syringe, and a diluent to achieve conception rates at least as good as conventional prior art device and procedure conception rates.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: January 31, 2017
    Inventor: Brad K. Stroud